Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Novo Nordisk is planning a higher-dose version (CagriSema 2.4/7.2 mg, pairing standard cagrilintide with Wegovy HD-level semaglutide) in a new Phase 3 trial starting H2 2026
The FDA has not yet accepted the recommendations, and inclusion on a compounding list would not constitute FDA approval or establish efficacy, safety, quality, an accepted indication or a standard dose
Although these medications are effective for glycemic control and weight loss, they do not replace the need for structured dietary guidance (Evert et al., 2013
Which Deployment Model leads the market
Treatment is not specifically licensed for menopausal weight gain but may be prescribed if you meet obesity treatment criteria during the menopausal transition
